Activation of adenylyl cyclase by endogenous Gs-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT7 receptor expression

被引:33
作者
Andressen, KW [1 ]
Norum, JH [1 ]
Levy, FO [1 ]
Krobert, KA [1 ]
机构
[1] Univ Oslo, Dept Pharmacol, N-0316 Oslo, Norway
关键词
D O I
10.1124/mol.105.015396
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human 5-hydroxytryptamine(7) (5-HT7) receptors display characteristics shared with receptors believed to form a tight physical coupling with G protein in the absence of ligand. Some receptors apparently preassociated with G(i/o) and G(q/11) are reported to inhibit the signaling of other similarly coupled G protein-coupled receptors by limiting their access to activate a common G protein pool. Therefore, we determined whether 5-HT7 receptor expression was sufficient to limit signaling of endogenously expressed G(s)-coupled receptors in human embryonic kidney (HEK) 293 cells. Using the ecdysone-inducible expression system, which allows for the titration of increasing receptor density in the same clonal cell line, we compared the effects of 5-HT4(b) and 5-HT7(a,b,d) receptor expression on adenylyl cyclase (AC) stimulation by the endogenous G(s)-coupled beta-adrenergic (beta AR) and prostanoid EP (EPR) receptors. beta AR- and EPR-stimulated AC activity was attenuated by 5-HT7 receptor expression in both membrane preparations and intact HEK293 cells. beta AR- and EPR-stimulated AC activity was unaffected by expression of the G(s)-coupled 5-HT4 receptor. The mechanism of this heterologous desensitization seems independent of protein kinase A activation, nor does it occur at the level of G protein activation because 1) beta AR- and EPR-stimulated AC activity was not restored to control values when G alpha(s) was overexpressed; and 2) beta(1)AR and beta(2)AR activation of G alpha(s) was unaffected by the expression of 5-HT7 receptors. In addition, overexpression of AC isoforms was unable to rescue beta AR- and EPR-stimulated AC activity. Therefore, 5-HT7 receptors probably limit access and/or impede activation of AC by beta AR and EP receptors. Although the 5-HT7 receptor may preassociate with G protein and/or AC, the mechanism of this heterologous desensitization remains elusive.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 36 条
[1]  
Adham N, 1998, J PHARMACOL EXP THER, V287, P508
[2]   Allosteric modulation of the human 5-HT7A receptor by lipidic amphipathic compounds [J].
Alberts, GL ;
Chio, CL ;
Im, WB .
MOLECULAR PHARMACOLOGY, 2001, 60 (06) :1349-1355
[3]   STOICHIOMETRY OF RECEPTOR-GS-ADENYLATE CYCLASE INTERACTIONS [J].
ALOUSI, AA ;
JASPER, JR ;
INSEL, PA ;
MOTULSKY, HJ .
FASEB JOURNAL, 1991, 5 (09) :2300-2303
[4]   Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor [J].
Baker, LP ;
Nielsen, MD ;
Impey, S ;
Metcalf, MA ;
Poser, SW ;
Chan, G ;
Obrietan, K ;
Hamblin, MW ;
Storm, DR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17469-17476
[5]   OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].
BLACK, JW ;
LEFF, P .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162
[6]   5-HT4 Receptors [J].
Bockaert, J. ;
Claeysen, S. ;
Compan, V ;
Dumuis, A. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (01) :39-51
[7]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[8]   Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs [J].
Bruheim, S ;
Krobert, KA ;
Andressen, KW ;
Levy, FO .
RECEPTORS & CHANNELS, 2003, 9 (02) :107-116
[9]  
CHIDIAC P, 1994, MOL PHARMACOL, V45, P490
[10]  
Claeysen S, 1999, MOL PHARMACOL, V55, P910